Mankind Pharma Limited — PPTs, 05-11-2024: Investor Presentation

Mankind Pharma reported a 13.6% YoY revenue growth in Q2 FY25, reaching ₹3,077 crore, driven by a strong performance in both domestic and consumer healthcare segments. The company maintains a robust EBITDA margin of 27.7%. Recent strategic expansions, including acquiring BSV, enhance its chronic care portfolio. Mankind continues to outperform industry metrics, notably in chronic therapies, and is focused on sustainable growth and innovation across its product lines. The investor presentation is available on their website.